Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics

Overview
Date Founded

1998

Headquarters

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158

Type of Company

Public

Employees (Worldwide)

618

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Contact Data
Trying to get in touch with decision makers at Nektar Therapeutics? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Operating Officer & Chief Financial Officer

Secretary, Senior Vice President & General Counsel

Senior Vice President & Chief Commercial Officer

Senior Vice President, Finance & Chief Accounting Officer

Chief Research & Development Officer

Senior Vice President, Clinical Development & Chief Medical Officer

Vice President & Head of Discovery & Research

Senior Vice President, Clinical Development & Head of Nektar's Immunology Program

Senior Vice President & Head of Development

Board of Directors

Co-Founder at Biota Technology, Inc.

Founder at Numenor Ventures LLC

Executive Vice President & Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

President & Chief Executive Officer at Nektar Therapeutics

Former Chief Operating Officer, Trustee & Executive Vice President at Sanford Burnham Prebys Medical Discovery Institute

Vice Chairman, President & Chief Executive Officer at Schering Berlin, Inc.

Co-Founder at Incyte Corp.

Paths to Nektar Therapeutics
Potential Connections via
Relationship Science
You
Nektar Therapeutics
Owners & Shareholders
Details Hidden

PRIMECAP invests primarily common stocks or securities with common stock characteristics, bonds and cash/cash equivalents. The firm utilizes fundamental research and bottom-up stock picking to construct portfolios. The main sources of information for research purposes include financial publications, inspections of corporate activities, research materials by others such as sell-side analysts, companies' annual reports and any related filings and press releases, meetings with executives of companies and their suppliers, competitors, customers, etc. All portfolios are built with the best ideas of each of the managers within the multi-manager investment process. PRIMECAP's investment strategy does not employ short sales or margin transactions, nor does it permit investments in derivatives or currency hedging. The firm follows an investment approach based on four key principles including commitment to fundamental research, long-term investment horizon, emphasis on individual decision-making and focus on value.

Details Hidden

Great Point Partners seeks to achieve positive excess returns by investing in publicly traded biotechnology, healthcare information technology, medical device, medical diagnostic and specialty pharmaceutical companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Great Point's hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. They target fast-growing, technology- driven small-cap companies. In addition, Great Point manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies.

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm's in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech's investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Recent Transactions
Details Hidden

Nektar Therapeutics issued USD Common Stock

Details Hidden

Nektar Therapeutics, Aerogen, Inc. purchase Aerogen Ltd.

Details Hidden

Nektar Therapeutics issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Accountant

Advised onNektar Therapeutics purchases Shearwater Corp.

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Legal Advisor

Advised onNektar Therapeutics issued Common Stock

Legal Advisor

Advised onNektar Therapeutics issued Common Stock

Head, Healthcare Investment Banking

Advised onNektar Therapeutics issued Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Legal Advisor

Partner at Cadwalader, Wickersham & Taft LLP

Advisor

Chief Technical Operations Officer at Amunix, Inc.

Clients

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Stats and Financials As of 2018
Market Capitalization
$3.71B
Total Enterprise Value
$4.89B
Earnings Per Share
$3.78
Revenue
$1.19B
EBITDAMargin
58.39%
Net Profit
$681M
EBITDA
$697M
Total Equity
$1.72B
Total Debt
$309M
Enterprise Value Sales
4.1x
TEVNet Income
7.18x
Debt TEV
0.06x
Enterprise Value EBITDAOperating
7.02x
Five Year Compounded Annual Growth Rate Of Revenue
51.62%
Three Year Compounded Annual Growth Rate Of Revenue
72.92%
Non-Profit Donations & Grants
Political Donations
$6,500
2012
Investments
Details Hidden

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

Investors
Details Hidden

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Suppliers
Enzon Pharmaceuticals Inc. Industrial Machinery & Manufacturing | Piscataway, NJ

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.

ImaginAb, Inc. Medical Support Services | INGLEWOOD , CA

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, QC

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nektar Therapeutics. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nektar Therapeutics's profile does not indicate a business or promotional relationship of any kind between RelSci and Nektar Therapeutics.